US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

Semaglutide · cycle length · research use only

How long is a semaglutide cycle? Why a GLP-1 agonist isn't 'cycled' — and the trial that settles it.

Search 'semaglutide cycle length' and you'll get the on/off framing people apply to BPC-157 or a growth-hormone secretagogue — run it for X weeks, then take a break. For a mono GLP-1 agonist that framing is a category error, and semaglutide happens to have the cleanest continuation-versus-stop experiment in the whole class. STEP 4 (Rubino et al., JAMA 2021) put everyone through a 20-week dose-escalation lead-in, then randomised participants either to continue semaglutide 2.4 mg or switch to placebo, and followed them to week 68. The continuers lost a further ~7.9% of body weight; the group switched off the drug regained ~6.9% — the two curves splitting apart the moment treatment stopped. The STEP 1 extension (Wilding et al., 2022) tells the same story over a longer window: about a year after stopping semaglutide, participants had regained roughly two-thirds of the weight they'd lost. A 2025 BMJ meta-analysis put class-wide regain near 60% of lost weight by one year. There is no on/off 'cycle' arm anywhere in the semaglutide literature — the trials study it as continuous therapy and study stopping as stopping, not as a scheduled break. This page lays out what semaglutide's own trials establish, why the cycling concept doesn't transfer, and the one genuine schedule that does exist: the multi-month titration ramp. It is a research reference summarising published trial data and pharmacology — not a human-use schedule, not dosing or medical advice.

Retatrutide — $199.99Semaglutide dosage & titration

'Cycling' is a bodybuilding-peptide concept — it doesn't transfer to a GLP-1 agonist

The on/off cycling idea comes from repair and growth-hormone peptides, where the rationale is either caution (no long-term human data) or a genuine kinetic driver (pulsing a GH secretagogue to preserve receptor responsiveness). A mono GLP-1 agonist has neither as a reason to schedule breaks. In the metabolic-agonist literature semaglutide is studied as continuous therapy, and importing a 'weeks on, weeks off' block from a different peptide class misreads what the compound is and how it was actually trialled.

How repair-peptide cycling differs →

STEP 4 is the field's cleanest continue-vs-stop trial

Where most compounds only infer discontinuation effects, semaglutide has a purpose-built randomised test. STEP 4 (Rubino et al., JAMA 2021) escalated everyone for 20 weeks, then split them: continue semaglutide 2.4 mg, or switch to placebo. By week 68 the continuers had lost a further ~7.9% of body weight while the switched-off group regained ~6.9% — a divergence that began as soon as the drug was withdrawn. It is one of the most direct answers to 'do you cycle off semaglutide' available, and the answer it gives is that stopping reverses the effect rather than banking it.

Adverse-event profile →

STEP 1 dosed continuously for 68 weeks — and stopping undid most of it

The pivotal STEP 1 trial (Wilding et al., NEJM 2021) dosed semaglutide continuously for 68 weeks to ~15% mean weight loss, with no on/off arm. Its extension study (2022) then followed participants after treatment ended and found roughly two-thirds of the lost weight had returned within about a year off the drug. Reading a fixed 68-week trial as a 'recommended cycle' repeats the mistake the preclinical peptide pages make: a study endpoint is not a schedule — and the follow-up shows what a break actually does here.

The 68-week response curve →

Why trialists frame it as chronic therapy, not a cycle

The STEP 4 and extension data are why the field describes obesity as a chronic condition needing ongoing treatment: the effect holds while the drug is on board and largely reverses when it comes off. That is the published position on duration for the GLP-1 class — continuous treatment to maintain the effect, not a fixed run followed by a planned rest. Any page presenting semaglutide as a compound you 'cycle off' is applying a framework its own randomised continuation trial points directly away from.

Retatrutide vs semaglutide →

The one genuine schedule: the titration ramp

The closest thing semaglutide has to a 'schedule' is dose escalation, not a cycle. The Wegovy label steps the weekly dose up gradually — 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg — over roughly four-week intervals, a ramp designed to limit the gastrointestinal side effects that cluster during escalation. That is a real, published structure worth understanding, and it's an ascending ladder rather than an on/off loop. The dosage page walks through the titration steps and the microgram-draw reconstitution math for each stage.

Titration ladder & recon math →

Research-use framing (and why Titan lists retatrutide instead)

Everything here summarises published clinical-trial designs and pharmacology reproduced as a research reference for laboratory and in-vitro modelling — not instructions for human use, and not a claim of efficacy or an optimal schedule in people. Titan does not stock semaglutide; the in-house-tested metabolic reagent we carry is retatrutide, a GLP-1/GIP/glucagon triple agonist studied in the same continuous-therapy way. Nothing on this page is medical or dosing advice.

Lab testing & COA workflow →

The detail, in plain terms

Semaglutide 'cycle length', separated into evidence and assumption.

A plain-terms split between what semaglutide's own trials establish about duration and the on/off 'cycle' assumptions imported from unrelated peptide classes. The trial figures are continuous-treatment and randomised continue-vs-stop data from semaglutide's own STEP programme; the 'cycle' figures have no controlled-trial basis for this drug class. Reproduced as a research reference, not a human-use schedule.

Validated 'cycle length'
None. No trial of semaglutide tested an on/off cycle. It was studied as continuous therapy, and its withdrawal trial studied stopping outright — not cycling.
Continue-vs-stop trial
STEP 4 (Rubino et al., JAMA 2021): 20-week lead-in, then continue vs switch-to-placebo. Continuing → ~7.9% further loss by week 68; stopping → ~6.9% regain.
Pivotal trial duration
STEP 1 (Wilding et al., NEJM 2021): 68 weeks continuous; ~15% mean weight loss, no on/off arm.
On discontinuation (long window)
STEP 1 extension (2022): ~two-thirds of lost weight regained within ~52 weeks of stopping semaglutide.
Class-wide regain estimate
~60% of lost weight regained by one year (BMJ 2025 meta-analysis; liraglutide/semaglutide/tirzepatide).
Trialists' stated model
Chronic condition requiring long-term therapy — continuous treatment to maintain effect, explicitly not an on/off cycle.
The real schedule that exists
Dose titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, stepped up over ~4-week intervals to limit GI effects — an ascending ladder, not a cycle.
Titan catalog status
Semaglutide not stocked. Titan's in-house-tested metabolic reagent is retatrutide ($199.99), a triple agonist trialled the same continuous way.

Questions researchers ask

Before you order.

How long should a semaglutide cycle be?
The premise doesn't fit the drug. Semaglutide is a mono GLP-1 agonist, and its trials did not use on/off cycles — STEP 1 (NEJM 2021) dosed continuously for 68 weeks, and STEP 4 (JAMA 2021) tested continuing versus stopping rather than cycling. There is no research-validated 'cycle length' because the class isn't cycled; it's studied as continuous therapy. Any specific 'X weeks on, then off' figure you see for semaglutide is imported from repair or growth-hormone peptides and has no controlled-trial basis for this compound. This page is a research reference summarising that evidence, not a human-use schedule.
Do you have to cycle off semaglutide?
Semaglutide has the field's cleanest experiment on that question, and it points the other way. STEP 4 (Rubino et al., JAMA 2021) randomised participants after a 20-week lead-in to continue semaglutide or switch to placebo: by week 68 the continuers had lost a further ~7.9% while the group taken off regained ~6.9%. The STEP 1 extension found roughly two-thirds of lost weight returned within a year of stopping. Trialists concluded obesity behaves as a chronic condition requiring long-term therapy, so in the research context these agents are framed as continuous rather than cycled. Nothing here is medical advice; it summarises what the trials reported.
Why is semaglutide not cycled like BPC-157 or CJC-1295/ipamorelin?
Because the reasons those peptides are cycled don't apply. BPC-157's cycling convention rests on the absence of long-term human safety data (a caution argument), and growth-hormone secretagogues like CJC-1295/ipamorelin are pulsed to preserve pituitary receptor responsiveness (a mechanism-based driver). A mono GLP-1 agonist has neither — no demonstrated desensitisation requiring breaks, and it was trialled as continuous therapy with a randomised continue-vs-stop arm rather than an on/off cycle. Same word, 'cycle', but a completely different underlying logic.
Is there any real 'schedule' for semaglutide?
Yes — but it's titration, not a cycle. The Wegovy label escalates the weekly dose gradually (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) over roughly four-week intervals to reach the maintenance target, a ramp designed to limit the gastrointestinal side effects that cluster during dose escalation. That is an ascending ladder with a defined structure, not an on-then-off loop. The dosage page covers the titration steps and the microgram-draw reconstitution math for each stage.
Does Titan sell semaglutide?
No. Titan Peptide Lab does not stock semaglutide. The in-house-tested metabolic research reagent we carry is retatrutide ($199.99), a GLP-1/GIP/glucagon triple agonist studied in the same continuous-therapy manner. Everything on this page is a research reference summarising published trial data on semaglutide — supplied for context, not as dosing or medical advice, and not for human or animal consumption.

Related reading

Before you check out.